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Abstract
INTRODUCTION—Changes in glucose levels may represent a powerful metabolic indicator for 
dementia in African Americans with diabetes. It is unclear whether these changes also occur in 
Caucasians.
METHODS—A secondary data analysis using electronic medical records from 5228 African 
Americans and Caucasians 65 years and older. Mixed effects models with repeated serum glucose 
measurements were used to compare changes in glucose levels between African Americans and 
Caucasian patients with and without incident dementia.
RESULTS—African Americans and Caucasians with diabetes had significantly different changes 
in glucose levels by dementia status (p<0.0001). African Americans experienced a significant 
decline in glucose levels before the dementia diagnosis (estimated glucose decline 1.3421 mg/dL 
Corresponding Author: Hugh C. Hendrie, MB, ChB, DSc, Indiana University Center for Aging Research, 1101 W 10th St., 
Indianapolis, IN 46202, hhendri@iupui.edu, Phone: (317) 274-9107, Fax: (317) 274-9305. 
Declaration of Interests: No authors have any conflicts of interest.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Alzheimers Dement. Author manuscript; available in PMC 2019 December 01.
Published in final edited form as:
Alzheimers Dement. 2018 December ; 14(12): 1572–1579. doi:10.1016/j.jalz.2018.03.008.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
per year, p<0.0001) than those who did not develop dementia. Caucasians with and without 
dementia showed stable glucose levels over time (p=0.3071).
DISCUSSION—Significant changes in glucose levels precede dementia in African American 
patients with diabetes but not in Caucasians.
Keywords
dementia; Alzheimer’s disease; longitudinal risk factors; diabetes; glucose levels; African 
Americans; Caucasians; electronic medical records; early detection
1. Introduction
Type 2 diabetes is increasing in the United States particularly for African Americans [1, 2]. 
African Americans also have higher rates of diabetes complications and poorer glycemic 
control than Caucasians [3–5]. The reasons for these discrepancies are unclear. It has been 
suggested that a combination of socio-economic, clinical, health care and self-management 
factors may explain the greater severity in African Americans [5–8]. Metabolic differences, 
involving insulin resistance, have also been reported between African Americans and 
Caucasians [9, 10]. Type 2 diabetes, particularly in midlife, has been reported as a risk factor 
for cognitive decline [11–13] and for dementia but again the association appears to be 
stronger in African Americans, where dementia rates are also higher, as compared to 
Caucasians [3, 13–16].
The possible pathophysiological pathways explaining the relationship between diabetes and 
dementia remain uncertain. Insulin resistance associated with variations in cerebral glucose 
uptake has been implicated [17]. A previous study by Crane and colleagues suggested that 
the effect may be mediated through elevated blood glucose levels among individuals with or 
without diabetes [18]. There have been few reports on change or variability of glucose levels 
in the lengthy pre-dementia period. In a previous paper we reported that high glucose levels 
in African Americans with diabetes were followed by a significant decline in these levels 
before dementia diagnoses [19]. However, in participants without diabetes there was no 
difference in the changes of glucose levels between participants who developed incident 
dementia and those without dementia. These changes, we hypothesized, may represent a 
powerful pre-symptomatic metabolic indicator for dementia in people with diabetes. In order 
to determine whether a similar glucose trajectory can be seen in Caucasian patients with 
diabetes and to compare glucose trajectories prior to dementia diagnosis between African 
Americans and Caucasians, we analyzed data from a large cohort of both African Americans 
and Caucasians with diabetes attending a city-wide community health system using data 
from their electronic medical records. The purpose of this paper is to report on the results 
from this analysis.
2. Methods
2.1. Study Population
The study population was defined by patients who received care at Eskenazi Health Services 
(an urban health care system in Indianapolis, IN) from January 1, 1992 to December 31, 
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2014, had a diagnosis of diabetes, and were 65 years or older during that time frame (total 
number of patients: 10205). Data for these patients were obtained from electronic medical 
records (EMR) that include diagnoses, laboratory test results, and medication prescriptions. 
For each individual we retrieved serum glucose measures associated with outpatient visits, 
ICD-9 codes for diabetes, dementia, and common comorbidities (diabetes: 250.*; dementia: 
290.*, 294.*, 331.*, 291.2, 310.0, 333.0, 797) and the use of diabetes medications classified 
as insulin only, oral antidiabetic medication only, or both insulin and oral medications. 
Height and weight measures were retrieved to calculate body mass index (BMI). In addition, 
ICD-9 codes from the EMR were used to define diabetes complications including 
hypoglycemia (hypoglycemia: 250.3, 250.8, 251.0, 251.1, 251.2, 270.3, 775.0, 775.6, 
962.3). This analysis included individuals with a history of diabetes and who were either 
African American or Caucasian. Individuals belonging to other racial groups were excluded 
from the analyses (n=665). In addition, we excluded 484 patients with prevalent dementia 
and another nine patients with missing information on gender leaving 9074 eligible patients 
in the analysis.
2.2. Statistical Analyses
Our analysis focused on longitudinal change in glucose levels prior to dementia diagnosis 
and whether these changes differed between African American and Caucasian groups. 
Patients who had a diagnosis of dementia prior to their first glucose measures were excluded 
from the analysis. Since we were interested in the within-person changes in glucose levels 
prior to dementia diagnosis, only patients with at least two glucose measures before reaching 
study endpoints were included in this analysis. In order to minimize potential influences 
from outlier observations, we excluded glucose measures below the first percentile or above 
the 99th percentile in the overall patient population.
To examine changes in glucose levels prior to dementia diagnosis, we aligned the timing of 
glucose measurements to an index time point defined as the date of the first diagnosis of 
dementia using ICD-9 codes for patients with dementia diagnosis or as date of death for 
those deceased without dementia or date of last clinic encounter in the EMR for surviving 
patients without dementia. Repeated serum glucose measures prior to index times were 
included as the dependent variable in this analysis. In all of our statistical models, index time 
was coded as time zero. For example, a participant with glucose measured at 1999 and a 
diagnosis of dementia in 2007 would have this measurement time coded as −8, indicating 
that this glucose measure was obtained 8 years prior to dementia diagnosis. Since we were 
interested in within-person changes in glucose levels, only patients with at least two glucose 
measures before index time were included in this analysis.
Demographic characteristics and comorbidities were compared using chi-square tests for 
categorical variables and analysis of variance (ANOVA) for continuous variables by both 
dementia status and racial group. Linear mixed effects models with unstructured variance 
covariance structure were used to explore three-way interactions among time, dementia 
status and race while adjusting for demographic variables including age, gender, BMI, and 
various medical conditions. A significant three-way interaction would indicate racial 
differences in changes of glucose levels between patients with dementia and those without. 
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Following a significant three-way interaction among time, dementia status and race, we used 
mixed effects models with repeated glucose measures in African Americans and Caucasians 
separately to further examine glucose change over time in each of the two racial groups.
Additional analyses were conducted to determine the robustness of our model results and to 
detect the subgroups that may account for the observed differences. We repeated the mixed 
effects models in several subsets of the study sample: by excluding individuals with 
cerebrovascular disease, those who were not taking antidiabetic medications, those with 
cerebrovascular disease and not taking anti-diabetic medications, and those with 
hypoglycemia. The statistical software SAS version 9.4 was used for the analyses.
3. Results
Out of the 9074 eligible patients for the analysis, we excluded 739 subjects who had no 
glucose measure or only one glucose measure, and 3107 patients for missing covariates 
(mostly BMI). A total of 5228 individuals with diabetes and at least two glucose measures 
were included in this analysis. There were 913 participants diagnosed with dementia during 
the course of the study. The median length of time from the first glucose measure to index 
time for African Americans was 13.8 years (interquartile range: 9.3, 17.8) and 12.2 years 
(interquartile range: 8.5, 16.5) for Caucasians. The average number of glucose measures per 
person was 2.2 per year and there was no difference between the two racial groups 
(p=0.3628). The number of glucose measures per person per year did not differ by dementia 
status within African Americans or Caucasians.
Demographic characteristics and comorbidities by dementia status within each racial group 
are presented in Table 1. In both African Americans and Caucasians, participants with 
dementia were significantly older, had lower BMI, and lower percentages of COPD, 
arthritis, cancer, hyperlipidemia, and renal disease, but higher percentages of depression and 
stroke.
In Table 2, we present results of the mixed effects model examining changes in glucose over 
time including a significant three-way interaction among time, dementia status, and race 
while adjusting for baseline age, gender, and BMI indicating significant differences in 
glucose change by dementia status in the two racial groups. While Caucasian participants 
with dementia showed similar and stable glucose levels over time compared to Caucasian 
participants without dementia (estimated glucose decline of 0.2729 mg/dL per year, 
p=0.3071), African American participants with dementia had a significant decline in glucose 
levels prior to dementia diagnosis compared to African American participants without 
dementia (estimated glucose decline 1.3421 mg/dL per year, p<0.0001). Estimated glucose 
trajectories from the mixed effects model in Table 2 are illustrated in Figure 1 for African 
Americans with dementia, African Americans without dementia, Caucasians with dementia 
and Caucasians without dementia. African American participants with incident dementia had 
significantly higher glucose levels at least two years before their dementia diagnosis than 
those without dementia (p=0.0202). In Caucasians, there were no significant changes in 
glucose levels in both participants with dementia and those without dementia (p=0.3071). 
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Results from adjusting for additional comorbid conditions were similar (see eTable 1 in 
Supplement).
In order to determine whether there were racial differences in diabetes severity and whether 
the difference in severity accounted for the differences in glucose trajectories, we compared 
the rates of diabetes complications among participants with and without dementia by race 
(Table 3). African Americans had higher total numbers of diabetic complications and also 
higher rates of having at least one complication than Caucasians. Using the total number of 
diabetic complications as a measure of diabetes severity, we added the number of 
complications and the interaction between the number of complications and time to the 
mixed model in Table 2 (eTable 2). Patients with more complications showed significantly 
greater decline in glucose levels over time. However, the difference in glucose trajectories 
between Caucasians and African Americans were similar to those reported in Table 2 even 
after adjusting for the number of diabetic complications.
To determine whether the racial difference in glucose change over time reported in Table 2 
was related to cerebrovascular disease or poor glucose control, we conducted additional 
sensitivity analyses in certain subsets of the participant sample (Supplemental document). 
The same three-way interaction mixed effects model was used by excluding participants 
with cerebrovascular disease (eTable 3). We re-ran the model using participants who were on 
anti-diabetes medications (eTable 4) and another model by excluding participants with 
cerebrovascular disease and including only those on antidiabetic medications (eTable 5). We 
also fitted the mixed effects models by excluding participants with hypoglycemia (eTable 6). 
Racial differences in glucose change over time between participants with dementia and 
without remained in all the models in the sensitivity analyses suggesting that the observed 
racial differences were not explained by differences in cerebrovascular disease, anti-diabetic 
medication use or hypoglycemia. Comparisons of characteristics between patients included 
in the analyses and those excluded due to the lack of repeated glucose measures or missing 
covariates are also included (see eTable 7). Patients included in our analysis sample were 
more likely to be African American, female, younger, and had higher rates on a number of 
medical conditions than those excluded from our analysis.
A subset of 3176 patients also had repeated hemoglobin A1C measures. As hemoglobin A1c 
reflects a more integrated measure of blood sugar control than a single time point measure of 
blood glucose we also fitted mixed effects models with repeated hemoglobin A1C as the 
dependent variable to examine the three-way interaction among race, dementia group and 
time while adjusting for baseline age, gender and BMI in this subset. A significant three way 
interaction on hemoglobin A1C was seen with similar trajectories to those for glucose levels 
(see eTable 8).
4. Discussion
In this analysis of repeated glucose levels obtained up to 22 years before the diagnosis of 
dementia from a large cohort of patients with diabetes attending the Eskenazi health system 
clinics, we found a significant difference in changes in glucose levels by dementia status 
between African Americans and Caucasians. African Americans with diabetes who 
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developed dementia had significantly higher glucose levels than those who did not develop 
dementia and they also experienced a significant decline in their glucose levels in the years 
prior to the diagnosis of dementia compared to those who did not develop dementia. There 
was no significant difference in the change in glucose levels in the Caucasian population 
between participants who developed dementia and those who did not. The findings in the 
African American patients were similar to those we previously reported [19].
In our previous paper the difference in glucose trajectories between the dementia and non-
dementia groups in African American participants weakened when those with 
cerebrovascular disease were excluded from the analysis, suggesting that the difference in 
glucose trajectories may be explained to a large extent by cerebrovascular disease. In this 
analysis, however, excluding participants with cerebrovascular disease made little difference 
to the results (supplement eTable 3). It has been reported that African Americans have not 
only higher rates of dementia than Caucasians but that the dementia was more likely to have 
a vascular component [14, 20, 21]. As a large percentage of dementia in elderly people is 
mixed in nature [22, 23] this vascular component may not have been identified in those with 
dementia diagnoses in this analysis particularly for African Americans. The African 
American participants also had higher rates of stroke than Caucasians but not significantly 
so (p=0.1067). Type 2 diabetes in African Americans without dementia has been associated 
with evidence of both brain macrovascular and microvascular disease including measures of 
cortical atrophy and white matter lesions [1] supporting our previous hypothesis that the pre-
dementia decline in glucose levels may be a result of an early effect on brain metabolic 
homeostatic mechanisms during the dementing process [19].
In contrast there was no significant difference in the change in glucose levels in the 
Caucasian population between participants who developed dementia and those who did not. 
There are a number of possibilities to explain the African American/Caucasian differences in 
the association between glucose levels and incident dementia. It has been reported that 
diabetes is associated with higher rates of chronic complications in African Americans than 
in Caucasians and that glycemic control is also poorer among African Americans [3–5]. In 
our study the African American participants were more likely to have recorded 
hypoglycemia. They also had higher rates of retinopathy and nephropathy but not of vascular 
disease. Adjusting for diabetic complications however did not change the differences in 
glucose trajectories for either group (Supplement eTable 1). ICD-9 diagnoses of 
hypoglycemia were significantly more frequent in African Americans than in Caucasians 
and were significantly associated with the development of dementia in both groups. 
However when patients with diagnoses of hypoglycemia were excluded from the model the 
significant decline in glucose levels remained for the African Americans with dementia, 
albeit somewhat attenuated (see supplement eTable 6) indicating that rates of recorded 
hypoglycemia may explain some but not all of the differences between the groups.
Differences in diabetic treatment have been proposed as one explanation for the disparities 
in diabetes severity and glycemic control between African Americans and Caucasians [4]. In 
our study African American patients were more likely to be treated with insulin than 
Caucasians perhaps as a response to the higher glucose levels in African Americans. But 
adjusting for diabetic medication did not change the difference in glucose trajectories 
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between the two racial groups (see supplement eTables 4 and 5). Changes in the treatment of 
diabetes have occurred over the study period, particularly with the use of metformin which 
has been associated with better cognitive function [24, 25]. We intend to explore the possible 
implications of these therapy changes in a more detailed analysis of medication use.
Discrepancies in socio-economic, health care and self-management factors have also been 
proposed to explain the increased severity of diabetes in African Americans [5–8]. 
Unfortunately the records did not allow us to explore fully these factors. As in a previous 
paper which used this EMR system, we did include enrollment in Medicaid as a possible 
surrogate for socioeconomic status [26]. Although there was a higher percentage of African 
American on Medicaid than Caucasians, there was no difference between dementia groups. 
The Medicaid variable was not significant in any of the mixed effect models for repeated 
glucose or hemoglobin A1c. It should be noted that all the individuals were attendees at an 
urban safety net health care system.
Other possibilities have been suggested that may explain the differences in diabetic severity 
between African Americans and Caucasians including different pathophysiological 
mechanisms of insulin resistance and differences in insulin sensitivity [9, 27]. However 
these are beyond the scope of this analysis. One intriguing hypothesis which could explain 
the association between insulin resistance and pre-clinical brain regions controlling 
metabolism in dementia involves its effect on regional cerebral glucose uptake [17, 28]. It is 
worthy to note, however, that BMI levels (which are associated with insulin resistance) were 
relatively similar across ethnic groups in our cohorts.
In prior studies, high glucose levels in participants with diabetes have been associated with 
cognitive decline in middle-aged African Americans but not in Whites [3]. Crane et al. 
however reported that high glucose levels were associated with an increased risk for 
dementia among not only people with diabetes but also without, in a predominantly white 
population [18]. Our analysis focused on individuals with diabetes compared to less than 
10% with diabetes in the Crane study. Our cohort also had a larger number of recorded co-
morbidities than did the Crane cohort. The difference in results in regard to Caucasians may 
also be attributable to the differences in statistical methods used between the studies. Our 
studies examined how the change in glucose levels over time differed between participants 
who developed dementia and those who did not, while the Crane study did not explore the 
within-subject change in glucose levels. In our analysis glucose levels were recorded for an 
up to 22 year period before the diagnosis of dementia while the Crane study focused on 
glucose levels five years prior to dementia diagnosis.
In summary our results support the findings of our previous analysis that high glucose levels 
occurring many years before diagnosis in African Americans with diabetes are associated 
with an increased risk for dementia. As in our previous study, we also found that glucose 
levels decline as the participants progress to dementia, perhaps as a result of early disruption 
of the brain metabolic control mechanisms and representing therefore a pre-symptomatic 
metabolic indicator for future dementia in these patients. Caucasian participants with 
diabetes did not however show this relationship between glucose levels and dementia. The 
reason for this disparity is not clear at this time perhaps reflecting differences in glycemic 
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control as indicated by higher rates of hypoglycemia in African Americans with diabetes. 
Our findings certainly reinforce previous reports that clinicians need to be particularly 
vigilant in ensuring control of glucose levels in African American patients with diabetes. 
Further explorations of these racial differences may also lead to a greater understanding of 
the possible neuropathological and metabolic links between diabetes and dementia.
4.1 Strengths
The present study has a number of strengths, including the large number of participants and 
the lengthy follow up period. The use of EMR allowed access to repeated laboratory 
measures associated with outpatient visits. Although many research studies have measured 
blood glucose as part of a biomarker panel, few have had the resources to support the 
collection of repeated biomarker measures.
4.2 Limitations
This analysis was confined only to individuals with diabetes with repeated glucose 
measurements which was approximately 57.6% of the total sample. Our analysis sample 
included patients with a higher burden of comorbidities than those excluded because of 
missing comorbidities. An analysis conducted on a community based sample to confirm 
these results would be worthwhile. It was not possible from our database to distinguish 
between fasting and non-fasting glucose levels. Reports from previous studies have 
suggested that midlife rather than late life diabetes is a risk factor for dementia and that 
longer duration is associated with greater risk. Unfortunately our EMR system was unable to 
capture midlife data for all participants. The records did not allow us to explore fully some 
factors such as treatment compliance or socioeconomic issues which have also been 
identified factors which may explain variations in diabetic severity. It should be noted that 
all the individuals were attendees at an urban safety net health care system. One additional 
limitation lies in the use of clinical records rather than direct examination particularly for 
diagnoses such as dementia where dementia subtypes may not be clearly identified.
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Highlights
• There are racial differences in the relationship between glucose levels and 
dementia
• High glucose levels precede dementia in diabetic African Americans, not in 
Caucasians
• A significant decline in these levels occur in African Americans, not in 
Caucasians
• African American diabetics have higher rates of hypoglycemia
• The differences may reflect poorer levels of glycemic control in African 
Americans
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Research in Context
Systematic Review
The author’s review of the literature included PUBMED. Diabetes increases risk for 
dementia particularly in African Americans. High glucose levels have been identified as a 
possible mediating factor. There were few reports in the literature on change or variability 
in glucose levels in the pre-dementia period. The relevant citations are included in the 
manuscript.
Interpretation
The results confirm our previous findings of high glucose levels followed by decline 
occurring years prior to dementia in African Americans with diabetes but did not in 
Caucasians.
Future Directions
Our findings implicate possible mechanisms linking diabetes with dementia which should 
be explored further. 1) The association between diabetes and cerebral micro and macro 
vascular disease, which may be more common in African Americans. Cerebrovascular 
disease may affect brain regions associated with metabolic control. 2) The association 
may be stronger in African Americans because of differences in glycemic control or 
insulin sensitivity affecting regional cerebral glucose metabolism.
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Figure 1. 
Predicted mean glucose levels over time from mixed linear effects models for diabetes 
individuals with and without dementia diagnosis by race adjusting for baseline age, gender, 
and body mass index.
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Table 2
Results from mixed effects model with repeated glucose levels over time as the dependent variable in 
individuals with diabetes (n=5228).
Effect Estimate Standard Error Pr > |t|
Female −4.0056 1.3136 0.0023
Age at baseline 0.07330 0.08521 0.3896
African American −7.3265 1.4539 <.0001
BMI 0.2819 0.07059 <.0001
Group
 demented 2.0318 1.9339 0.2934
 Non demented Ref . .
Time −0.02115 0.09923 0.8312
Time*Group*Race <.0001
 Time*demented*African American −1.6324 0.2166 <.0001
 Time* demented *Caucasian −0.2729 0.2672 0.3071
 Time * non demented *African American −0.2903 0.1228 0.0181
 Time * non demented *Caucasian Ref . .
#
estimated glucose slope difference between African American with dementia and African Americans without dementia is β=−1.3421 and 
p<0.0001
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